Cargando…
ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer
Objective: Pancreatic cancer is one of the most malignant tumors, with rapid metastasis, high mortality rate, and difficult early screening. Currently, gemcitabine is a first-line drug for pancreatic cancer patients, but its clinical effect is limited due to drug resistance. It is particularly impor...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596206/ https://www.ncbi.nlm.nih.gov/pubmed/36214762 http://dx.doi.org/10.18632/aging.204324 |